MXPA06001327A - Factor trefoil3 (tff3) como objetivo para terapia anti-cancer. - Google Patents

Factor trefoil3 (tff3) como objetivo para terapia anti-cancer.

Info

Publication number
MXPA06001327A
MXPA06001327A MXPA06001327A MXPA06001327A MXPA06001327A MX PA06001327 A MXPA06001327 A MX PA06001327A MX PA06001327 A MXPA06001327 A MX PA06001327A MX PA06001327 A MXPA06001327 A MX PA06001327A MX PA06001327 A MXPA06001327 A MX PA06001327A
Authority
MX
Mexico
Prior art keywords
tff3
antibody
cancer
neutralizing agent
expression
Prior art date
Application number
MXPA06001327A
Other languages
English (en)
Spanish (es)
Inventor
Christoph Reinhard
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of MXPA06001327A publication Critical patent/MXPA06001327A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MXPA06001327A 2003-08-07 2004-08-05 Factor trefoil3 (tff3) como objetivo para terapia anti-cancer. MXPA06001327A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49317303P 2003-08-07 2003-08-07
US49843803P 2003-08-28 2003-08-28
PCT/US2004/025508 WO2005013802A2 (en) 2003-08-07 2004-08-05 Trefoil factor 3 (tff3) as a target for anti-cancer therapy

Publications (1)

Publication Number Publication Date
MXPA06001327A true MXPA06001327A (es) 2006-05-04

Family

ID=34138741

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06001327A MXPA06001327A (es) 2003-08-07 2004-08-05 Factor trefoil3 (tff3) como objetivo para terapia anti-cancer.

Country Status (9)

Country Link
US (2) US20080233046A1 (https=)
EP (1) EP1660136A4 (https=)
JP (1) JP2007501616A (https=)
KR (1) KR20060073589A (https=)
AU (1) AU2004263140A1 (https=)
CA (1) CA2534658A1 (https=)
IL (1) IL173333A0 (https=)
MX (1) MXPA06001327A (https=)
WO (1) WO2005013802A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1833991A4 (en) * 2004-12-22 2011-11-16 Auckland Uniservices Ltd TREFOIL FACTORS AND METHOD FOR THE TREATMENT OF PROLIFERATIVE DISEASES THEREWITH
US7601540B2 (en) * 2006-07-18 2009-10-13 Bristol-Myers Squibb Company Gamma secretase notch biomarkers
US20080199455A1 (en) * 2006-10-03 2008-08-21 Lobie Peter E Conformation specific antibodies that bind trefoil factors and methods of treating cancers and proliferation disorders using same
ES2332167B1 (es) * 2007-12-04 2010-10-25 Universidad Autonoma De Madrid Empleo de trefoil factor-family 3 (tff3) en el pronostico de sujetos diagnosticados con cancer colorectal.
WO2011060040A1 (en) * 2009-11-10 2011-05-19 Abraxis Bioscience, Llc Diagnostic and therapeutic applications of the u6 snrna
GB0920014D0 (en) 2009-11-13 2009-12-30 Medical Res Council Cell sampling device
EP2661620A4 (en) * 2011-01-08 2014-07-16 Astute Medical Inc METHOD AND COMPOSITIONS FOR DIAGNOSING AND PROGNOSING RENAL INJURY AND RENAL INSUFFICIENCY
WO2025166063A1 (en) 2024-01-31 2025-08-07 Bluerock Therapeutics Lp Igfbp2 in cell culture
CN120209138B (zh) * 2025-05-29 2025-10-03 杭州广科安德生物科技有限公司 Tff3、osm蛋白的抗体及其组合和在结直肠癌诊断中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063755A (en) * 1991-02-14 2000-05-16 The General Hospital Corporation Intestinal trefoil proteins
US5733748A (en) * 1995-06-06 1998-03-31 Human Genome Sciences, Inc. Colon specific genes and proteins
US6337195B1 (en) * 1995-06-06 2002-01-08 Human Genome Sciences, Inc. Colon specific genes and proteins
DE19701873C1 (de) * 1997-01-21 1998-06-04 Daimler Benz Ag Halterung einer Abgasrückführleitung am Motorgehäuse einer Brennkraftmaschine
US6261562B1 (en) * 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6465611B1 (en) * 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6476207B1 (en) * 1998-06-11 2002-11-05 Chiron Corporation Genes and gene expression products that are differentially regulated in prostate cancer
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
FR2810297B1 (fr) * 2000-06-16 2002-08-02 Cogema Distributeur automatique de couvercles sur des boites
US6991901B2 (en) * 2001-01-11 2006-01-31 Curagen Corporation Proteins and nucleic acids encoding same
JP2005512510A (ja) * 2001-05-16 2005-05-12 ノバルティス アクチエンゲゼルシャフト 予後および治療標的として乳癌で発現される遺伝子
WO2003004989A2 (en) * 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
DE10215320A1 (de) * 2002-04-02 2003-10-23 Metagen Pharmaceuticals Gmbh Verwendungen von TFF3 bindenden Substanzen zur Diagnose und Behandlung von Krebserkrankungen
AU2002349786A1 (en) * 2002-06-19 2004-01-06 Japan As Represented By The President Of The University Of Tokyo Method for diagnosis of colorectal tumors
CA2519630A1 (en) * 2003-03-20 2004-10-07 Dana-Farber Cancer Institute, Inc. Gene expression in breast cancer

Also Published As

Publication number Publication date
KR20060073589A (ko) 2006-06-28
WO2005013802A2 (en) 2005-02-17
IL173333A0 (en) 2006-06-11
WO2005013802A3 (en) 2006-03-23
US20050186212A1 (en) 2005-08-25
AU2004263140A1 (en) 2005-02-17
US20080233046A1 (en) 2008-09-25
CA2534658A1 (en) 2005-02-17
EP1660136A4 (en) 2007-02-07
EP1660136A2 (en) 2006-05-31
JP2007501616A (ja) 2007-02-01

Similar Documents

Publication Publication Date Title
US20240043541A1 (en) Methods for treating hematologic cancers
US20030194406A1 (en) P-cadherin as a target for anti-cancer therapy
KR20100067089A (ko) Ｔ 세포를 조정하기 위한 방법 및 조성물
CN101932604A (zh) EphB4作为诊断标记和作为卵巢癌的治疗靶标的用途
US20090142259A1 (en) Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
MXPA05014153A (es) Composiciones y metodoso para el diagnostico y tratamiento de tumor.
MXPA06001327A (es) Factor trefoil3 (tff3) como objetivo para terapia anti-cancer.
US7348418B2 (en) Carcinoma-related genes and polypeptides and methods of use thereof
US20100068198A1 (en) Targeting of alpha-1 or alpha-3 subunit of na+, k+-atpase in the treatment of proliferative diseases
JP2010505428A (ja) 癌及び癌転移の治療と診断のための組成物及び方法
JPWO2006093337A1 (ja) 癌の予防・治療剤
US20160187340A1 (en) Compositions, Kits, and Methods for the Modulation of Immune Responses Using Galectin-1
US8252267B2 (en) DKKL-1 splice product modulators for cancer diagnosis and therapy
EP2257299B1 (en) Modulation of srpx2-mediated angiogenesis
US20080193446A1 (en) Compositions and Methods for the Diagnosis and Treatment of Tumor
WO2005123127A2 (en) Methods for treating cancer using prss15 as a target
MX2007012216A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
CA2678555A1 (en) Amelioration of cellular stress response

Legal Events

Date Code Title Description
HC Change of company name or juridical status